Poster archive
Below is the poster archive. See the most recent posters here.
- AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage
- AVA6000, a novel preCISION medicine, targeted to the tumor microenvironment via FAP mediated cleavage
- Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1
- Half-life Extension Formatting of Human PD-L1 Antagonist Therapeutic Affimers
- Affimer® Anti-Idiotypic Binders: High-performing Critical Reagents for Diverse Clinical Needs
- Affimer® reagents facilitate affinity chromatography purification of IgG
- Affimer Anti-idiotypic Binders: Critical Reagents For Clinical Ligand Binding Assays
- Development And Validation Of Affimer-based Adalimumab-TNFa Complex Specific Reagents
- Generation and Formatting of an Affimer® Biotherapeutic for the Inhibition of the PD-L1/PD-1 Pathway: Proof of Concept in Mouse.
- A Platform Technology For The Rapid Generation Of Robust Anti-Idiotypic Binders For Clinical PK Assays
- Discovery, characterisation and pharmacokinetics of Serum Albumin Binding Affimer proteins that can be used for half-life extension
- Isolation of Affimer Therapeutics with Nanomolar Affinity to Human PD-L1 from a Synthetic Phage Display Library
- Fc fusion Affimer® Biotherapeutic Targeting PD-L1 Inhibits Tumour Growth in Mouse
- Affimer® reagents facilitate affinity chromatography purification of IgG
- Fc Fusion Affimer® Biotherapeutics: Generation of Potent Human and Mouse PD-L1 Antagonists
- Fc fusion Affimer® Biotherapeutic Targeting PD-L1 Inhibits Tumour Growth in Mouse
- Generation and Characterisation of Formatted Affimer® Biotherapeutics
- Fibrinogen targeted Affimers® can successfully modulate fibrin clot lysis in the presence of plasminogen inhibitor
- Generation and Formatting of Affimer® affinity binders for the Inhibition of the PD-L1/PD-1 Pathway
- Generation and Formatting of Affimer® Biotherapeutics for the Inhibition of the PD-L1/PD-1 Pathway
- Isoform specific inhibition of human SUMO proteins using Affimer® binders
- Affimer® Proteins – Next Generation Affinity Tools
- Allosteric inhibition of FcgRIIIa-IgG interactions using Affimers
- The Production and Characterisation of Affimer® In- Line Fusion Formats with High Affinity hPD-L1 Blockade and Half-life Extension for Immunotherapy
- Development and Characterisation of a LAG-3/ PD-L1 Bispecific Affimer® Biotherapeutic
- Turning a Negative to a Positive with Anti-metatype Affimer® Reagents